Open AccessLow serum iron as a possible risk factor for neuroleptic malignant syndrome
Author(s) -
Bhushan Subhash Patil,
Alka A Subramanyam,
Shipra L Singh,
Ravindra Kamath
Publication year - 2014
Publication title -
international journal of applied and basic medical research/international journal of applied and basic medical research
Language(s) - English
Resource type - Journals
eISSN - 2248-9606
pISSN - 2229-516X
DOI - 10.4103/2229-516x.136800
Subject(s) - neuroleptic malignant syndrome , bromocriptine , medicine , leukocytosis , dysautonomia , gastroenterology , serum iron , anemia , disease , hormone , prolactin
Neuroleptic malignant syndrome (NMS) is a rare, but fatal condition characterized by rigidity, fever, dysautonomia and altered consciousness along with elevated serum creatinine phosphokinase levels and leukocytosis. Treatment of NMS includes symptomatic and specific treatment with drugs like bromocriptine may be given. Risk factors for NMS include dehydration, parenteral antipsychotics and high potency antipsychotics. One of the important, but lesser known risk factors for NMS is low serum iron. Pronounced reduction in serum iron suggests that acute phase reactants do have a role in NMS. The present case report focuses on the importance of low serum iron as a risk factor for NMS.